Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica

National Registry of Patients With Atopic Dermatitis Under Treatment With Dupilumab and JAK Inhibitors Within the Costa Rican Social Security System

The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:

What are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?

What treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?

Participants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.

This is a national, multicenter, observational registry of patients with atopic dermatitis treated in dermatology referral centers in Costa Rica. The registry aims to document demographic characteristics, disease history, severity, comorbidities, treatment patterns, and longitudinal outcomes in patients receiving systemic immunosuppressants, biologic agents, or other advanced therapies in routine clinical practice.

Data will be collected prospectively and retrospectively from medical records and routine clinical assessments, including validated severity indices (e.g., EASI, SCORAD, DLQI), treatment exposure, adverse events, and therapeutic response over time. The registry will allow evaluation of real-world effectiveness, safety, and treatment persistence, as well as characterization of moderate-to-severe atopic dermatitis in the Costa Rican population.

This registry does not modify clinical management; all treatments are prescribed according to physician judgment and standard care.

Inclusion Criteria:

• Clinical diagnosis of atopic dermatitis according to accepted diagnostic criteria
• Moderate-to-severe disease requiring systemic or advanced therapy
• Receiving systemic immunosuppressive, biologic, or other advanced treatment as part of routine care
• Evaluated in participating dermatology centers in Costa Rica
• Available clinical records with baseline and follow-up information

Exclusion Criteria:

• Lack of sufficient clinical data for severity or treatment assessment